Detalles de la búsqueda
1.
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.
Blood
; 141(20): 2470-2482, 2023 05 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36821767
2.
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
Haematologica
; 109(4): 1184-1193, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37646659
3.
Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination.
Br J Haematol
; 202(6): 1091-1103, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37402627
4.
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Blood
; 137(19): 2634-2645, 2021 05 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33211842
5.
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 790-800, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33989558
6.
FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective study.
Br J Haematol
; 192(3): 504-513, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32621535
7.
Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
Br J Haematol
; 192(6): 1015-1019, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32436212
8.
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study.
Ann Hematol
; 100(10): 2529-2539, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34304287
9.
Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real-World Experience from 554 sequential core biopsies from a single centre.
Eur J Haematol
; 106(2): 267-272, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33159689
10.
Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.
Br J Haematol
; 191(2): 194-206, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32678948
11.
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial.
Ann Hematol
; 99(1): 105-112, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31776726
12.
Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
Br J Haematol
; 179(3): 471-479, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28857136
13.
The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
Br J Haematol
; 192(3): e84-e87, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33426648
14.
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.
Br J Haematol
; 175(4): 668-672, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27477167
15.
Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
Br J Haematol
; 195(5): 706-709, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34545952
16.
Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin Lymphoma.
Br J Haematol
; 171(2): 197-204, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26119524
17.
Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'.
Br J Haematol
; 191(3): 505-506, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33103782
18.
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
Lancet Oncol
; 15(4): 424-35, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24602760
19.
Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab.
Br J Haematol
; 184(3): 462-465, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29363752
20.
Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials.
Br J Haematol
; 185(2): 344-347, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29978458